{"id":26707,"date":"2022-10-17T08:30:46","date_gmt":"2022-10-17T12:30:46","guid":{"rendered":"https:\/\/www.cosprc.ca\/?p=26707"},"modified":"2022-10-24T13:17:27","modified_gmt":"2022-10-24T17:17:27","slug":"enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2","status":"publish","type":"post","link":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/","title":{"rendered":"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&rsquo;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires"},"content":{"rendered":"\n<p>octobre 2022<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"171\" src=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png\" alt=\"\" class=\"wp-image-26531\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-medium\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"97\" src=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2018\/10\/CRS-Logo-Abbrev-Opt1-c-300x97.jpg\" alt=\"\" class=\"wp-image-6116\" srcset=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2018\/10\/CRS-Logo-Abbrev-Opt1-c-300x97.jpg 300w, https:\/\/www.cosprc.ca\/wp-content\/uploads\/2018\/10\/CRS-Logo-Abbrev-Opt1-c.jpg 491w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-medium\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"86\" src=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-1-300x86.png\" alt=\"\" class=\"wp-image-26524\" srcset=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-1-300x86.png 300w, https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-1.png 603w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<p>Les m\u00e9dicaments biologiques biosimilaires (biosimilaires*) ont fait leur apparition sur le march\u00e9 canadien en 2009. Le premier biosimilaire ophtalmique pour injection intravitr\u00e9enne devrait \u00eatre lanc\u00e9 au Canada \u00e0 la fin de l\u2019automne 2022. Avec ce lancement, on pr\u00e9voit que l\u2019utilisation de biosimilaires au Canada augmentera rapidement.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/Biosimilars-October-18-2022-FRENCH.pdf\">Lisez la d\u00e9claration de position compl\u00e8te ici.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>octobre 2022 Les m\u00e9dicaments biologiques biosimilaires (biosimilaires*) ont fait leur apparition sur le march\u00e9 canadien en 2009. Le premier biosimilaire ophtalmique pour injection intravitr\u00e9enne devrait \u00eatre lanc\u00e9 au Canada \u00e0 la fin de l\u2019automne 2022. Avec ce lancement, on pr\u00e9voit que l\u2019utilisation de biosimilaires au Canada augmentera rapidement. Lisez la d\u00e9claration de position compl\u00e8te ici.<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[305],"post_tag":[],"content_type":[326],"class_list":["post-26707","post","type-post","status-publish","format-standard","hentry","category-pour-les-ophtalmologistes","content_type-enonce-de-principes-et-lignes-directrices"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&#039;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires - Practice Resource Centre<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&#039;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires - Practice Resource Centre\" \/>\n<meta property=\"og:description\" content=\"octobre 2022 Les m\u00e9dicaments biologiques biosimilaires (biosimilaires*) ont fait leur apparition sur le march\u00e9 canadien en 2009. Le premier biosimilaire ophtalmique pour injection intravitr\u00e9enne devrait \u00eatre lanc\u00e9 au Canada \u00e0 la fin de l\u2019automne 2022. Avec ce lancement, on pr\u00e9voit que l\u2019utilisation de biosimilaires au Canada augmentera rapidement. Lisez la d\u00e9claration de position compl\u00e8te ici.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Practice Resource Centre\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-17T12:30:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-24T17:17:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png\" \/>\n<meta name=\"author\" content=\"Admin Assistant\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin Assistant\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/\"},\"author\":{\"name\":\"Admin Assistant\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\"},\"headline\":\"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&rsquo;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires\",\"datePublished\":\"2022-10-17T12:30:46+00:00\",\"dateModified\":\"2022-10-24T17:17:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/\"},\"wordCount\":74,\"image\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/image-2.png\",\"articleSection\":[\"Pour les ophtalmologistes\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/\",\"name\":\"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d'ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires - Practice Resource Centre\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/image-2.png\",\"datePublished\":\"2022-10-17T12:30:46+00:00\",\"dateModified\":\"2022-10-24T17:17:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/image-2.png\",\"contentUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/image-2.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&#8217;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/\",\"name\":\"Practice Resource Centre\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cosprc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\",\"name\":\"Admin Assistant\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"caption\":\"Admin Assistant\"},\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/author\\\/h4gznwtqqyl8bwjg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d'ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires - Practice Resource Centre","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/","og_locale":"fr_FR","og_type":"article","og_title":"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d'ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires - Practice Resource Centre","og_description":"octobre 2022 Les m\u00e9dicaments biologiques biosimilaires (biosimilaires*) ont fait leur apparition sur le march\u00e9 canadien en 2009. Le premier biosimilaire ophtalmique pour injection intravitr\u00e9enne devrait \u00eatre lanc\u00e9 au Canada \u00e0 la fin de l\u2019automne 2022. Avec ce lancement, on pr\u00e9voit que l\u2019utilisation de biosimilaires au Canada augmentera rapidement. Lisez la d\u00e9claration de position compl\u00e8te ici.","og_url":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/","og_site_name":"Practice Resource Centre","article_published_time":"2022-10-17T12:30:46+00:00","article_modified_time":"2022-10-24T17:17:27+00:00","og_image":[{"url":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png","type":"","width":"","height":""}],"author":"Admin Assistant","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Admin Assistant","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#article","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/"},"author":{"name":"Admin Assistant","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75"},"headline":"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&rsquo;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires","datePublished":"2022-10-17T12:30:46+00:00","dateModified":"2022-10-24T17:17:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/"},"wordCount":74,"image":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png","articleSection":["Pour les ophtalmologistes"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/","url":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/","name":"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d'ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires - Practice Resource Centre","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#primaryimage"},"image":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png","datePublished":"2022-10-17T12:30:46+00:00","dateModified":"2022-10-24T17:17:27+00:00","author":{"@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75"},"breadcrumb":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#primaryimage","url":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png","contentUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2022\/10\/image-2.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-principe-conjoint-de-la-societe-canadienne-dophtalmologie-sco-sur-les-medicaments-biosimilaires-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cosprc.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"\u00c9nonc\u00e9 de principe conjoint de la Soci\u00e9t\u00e9 canadienne d&#8217;ophtalmologie (SCO) sur les m\u00e9dicaments biosimilaires"}]},{"@type":"WebSite","@id":"https:\/\/www.cosprc.ca\/#website","url":"https:\/\/www.cosprc.ca\/","name":"Practice Resource Centre","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cosprc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75","name":"Admin Assistant","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","caption":"Admin Assistant"},"url":"https:\/\/www.cosprc.ca\/fr\/author\/h4gznwtqqyl8bwjg\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-23 23:00:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/26707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/comments?post=26707"}],"version-history":[{"count":2,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/26707\/revisions"}],"predecessor-version":[{"id":26710,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/26707\/revisions\/26710"}],"wp:attachment":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/media?parent=26707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/categories?post=26707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/post_tag?post=26707"},{"taxonomy":"content_type","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/content_type?post=26707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}